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Abstract
Psychiatric symptoms are an increasingly recognised feature of movement disorders. 
Recent identification of causative genes and autoantibodies has allowed detailed 
analysis of aetiologically homogenous subgroups, thereby enabling determination of 
the spectrum of psychiatric symptoms in these disorders.  
This review evaluates the incidence and type of psychiatric symptoms encountered in 
patients with movement disorders. A broad spectrum of psychiatric symptoms was 
identified across all subtypes of movement disorder, with depression, generalised 
anxiety disorder and obsessive-compulsive disorder being most common. Psychosis, 
schizophrenia and attention deficit hyperactivity disorder were also identified, with 
the psychiatric symptoms often predating onset of the motor disorder.
The high incidence of psychiatric symptoms across such a wide range of movement 
disorders suggests a degree of common or overlapping pathogenic mechanisms. Our 
review demonstrates the need for increased clinical awareness of such co-morbidities, 
which should facilitate early neuropsychiatric intervention and allied specialist 
treatment for patients.
Keywords: Movement Disorders, Genetics, Immune mediated, Psychiatric 
phenotype.
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Introduction  
Psychiatric illness is increasingly recognised as a primary phenotypic component of 
many movement disorders.[1] This has led to increased reporting of such symptoms, 
often resulting in a broad range of psychiatric phenotypes associated with individual 
movement disorders. Examination of aetiologically homogenous groups provides 
clear definition when evaluating these symptoms as well as potentially allowing 
insights into the physiological mechanisms underlying psychiatric disturbance.
The exact mechanisms determining co-occurrence of psychiatric and motor symptoms 
remain largely unknown. The topographical organisation of sensorimotor, associative 
and limbic areas of the subthalamic nucleus (STN) and its interaction with both the
direct and indirect pathways of the basal ganglia, provides a potential anatomical
explanation for these co-existent symptoms (Figure 1).[2] Monoamine metabolism is 
also likely to influence these neural networks with dopaminergic therapy exacerbating 
Impulse Control Disorders (ICDs) in patients with idiopathic Parkinsons disease
(iPD), while loss of GABAergic neurons leads to dis-inhibition of nigral 
dopaminergic neurons in patients with X-linked dystonia-parkinsonism (DYT3).[3] 
Successful therapeutic use of Selective Serotonin Reuptake Inhibitors (SSRIs) and 
neuroimaging techniques also signify the importance of serotonin in mental health 
disorders, most markedly Major Depressive Disorder (MDD), anxiety disorders and 
Obsessive-Compulsive Disorder (OCD) (Figure 2).[4, 5]
This review seeks to better define the psychiatric phenotype associated with 
aetiologically homogenous movement disorders of both adult and paediatric onset. 
Discussion of all movement disorders is beyond the scope of this review, instead we 
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have sought to focus on those with and underlying genetic or immune-mediated 
aetiology with movement disorders as the dominant feature. An evaluation of the 
quality of the evidence is also included with emphasis on that from larger cohort and
case-control studies. 
Methods
We performed a systematic literature search of the PUBMED database using the key 
words psychiatry, psychiatric, alcohol abuse/dependence, schizophrenia, 
psychosis, major depressive disorder, bipolar disorder, generalised anxiety 
disorder, agoraphobia, specific phobia, social phobia, obsessive compulsive 
disorder, post-traumatic stress disorder, anorexia nervosa and bulimia nervosa 
in combination with each of the genetic or immune-mediated disorders. All those 
published in English and in peer-reviewed journals until March 2017 were included.   
Additional inclusion criteria were 1) identification of a genetic aetiology or 
immunological syndrome and 2) where the movement disorder was a predominant 
disease feature. Publications were excluded if the genetic or immunological testing 
was negative, not performed or movement disorder was not described in the clinical 
phenotype. Studies identified were divided according to the size of the cohort and 
whether there was comparison to a control group (Supplementary Figure 1): Case 
Reports (n=1) (Supplementary Table 1), Small Case Series (n<5) (Supplementary 
Table 2), Larger Case Series (n>5 patients) (Supplementary Table 3) and Case-
Control Studies (Supplementary Table 4). All evidence from larger case series (+) and 
case-control studies (++) are summarised in Tables 1-4. The (+) marker denotes 
features described in larger case series, but with no control groups and no statistical 
comparison of significance, (++) indicates a statistically significant elevation of 
Psychiatric co-morbidity in Movement Disorders
Peall et al 2017
5
psychiatric comorbidity compared to a control group. The key publications from these 
tables are discussed below. Population prevalence estimates for all major psychiatric 
disorders in adults and children are available for comparison (Supplementary Table 
5).
Parkinsonism
Genetic Parkinsonism
The clinical and genetic features of genetic parkinsonian disorders with evidence of 
psychiatric symptoms are summarised in Table 1.
(i) Autosomal Dominant Genetic Parkinsonism
The a-synuclein (SNCA) gene was the first to be identified in Parkinsons disease 
(PD).[6] Conflicting evidence has been noted in studies of SNCA (PARK1/4)
mutation positive cohorts with some observing severe depression, hallucinations and 
delusions, while case-control comparison found no significant difference in either the 
reported rate of depression (p=0.7) or lack of motivation (p=0.46).[7, 8] Studies of 
Leucine-rich repeat kinase 2 (LRRK2) (PARK8) mutation positive cohorts have 
tended to focus on mood disorders with Goldwurm et al (n=19) reporting increased 
rates of depression (69%), anxiety (62%) and irritability (56%), and a trend towards a 
pre-motor mood disorder when comparing mutation positive, matched, Ashkenazi 
Jewish pairs (OR=6.0, p=0.10).[9, 10] Comparison to those with idiopathic
Parkinsons disease (iPD) found increased rates of depression amongst those with 
LRRK2 mutations (p=0.001), while anxiety levels remain similar (p=0.33).[11, 12]
However, a large PD cohort (n=840) with proportionally few LRRK2 mutation 
Psychiatric co-morbidity in Movement Disorders
Peall et al 2017
6
positive cases (4.8%) identified similar rates of depression when comparing the 
G2019S LRRK2 mutation (p=0.90) to the remaining population.[13]
(ii) Autosomal Recessive Genetic Parkinsonism
Early case series of those with Parkin (PARK2) mutations found evidence of 
psychiatric symptoms in 56% of the cohort (n=24), with symptoms including 
depression, psychosis, and panic attacks. A quarter of cases developed these 
symptoms >5 years prior to onset of their motor symptoms, while 31% developed 
psychiatric symptomatology at a later time point.[14] A subsequent case-control study 
(146 Parkin mutation positive, 250 mutation negative controls) found psychiatric 
symptoms in only 9 cases with Parkin mutations, with symptoms spanning psychosis, 
panic attacks, depression, disturbed sexual behaviour and obsessive-compulsive (OC) 
symptoms.[15] Several studies have sought to compare early-onset PD (EOPD) cases
with and without Parkin mutations failing to identify distinct psychiatric markers.[16]
Other studies have sought to compare homozygotes, compound heterozygotes, 
heterozygotes and Parkin mutation negative controls using multiple diagnostic tools.
Other than a tendency towards higher rates of depression in the relatives of affected 
heterozygous Parkin mutation carriers, these studies have found little between group 
differences.[17-19]
Initial larger case series of those with PTEN-induced putative kinase 1 (PINK1)
(PARK6) mutations reported symptoms of mood disturbance, depression, anxiety and 
psychosis.[20-24] Other studies have sought to compare the psychiatric phenotype of
those with homozygous mutations to compound heterozygotes with conflicting 
results. Some found heterozygotes to have a generally milder phenotype, 
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predominantly involving depression and anxiety, while others have described a 
broader pattern including schizophrenia spectrum disorder and Obsessive-Compulsive 
personality disorder.[25-27] Certain psychiatric symptoms may pre-date the 
movement disorder, with one study reporting initial symptoms of depression (75%) 
and schizophrenia or affective disorder (55%) (n=20).[28]
iii) Other forms of genetic parkinsonism
Several studies have observed an increased risk of parkinsonism in patients with 
Gauchers disease (GBA mutation). Results from case-control studies have varied 
dependent upon the control group to which the cases have been compared. Alcalay 
and colleagues reported no significant difference in depression scores in 33 GBA
mutation positive cases compared to 114 mutation-negative EOPD individuals.[29]
However, when compared to iPD cases an excess of depressive symptoms (p=0.05, 
p<0.05 and p=0.013), anxiety (p=0.007), apathy and indifference (p=0.043) has been 
observed.[30-32] Psychiatric symptoms in patients with Niemann Pick disease Type 
C (NPC) are most prevalent in those with the adult-onset form of the disorder, with up 
to (45% (n=13) reporting symptoms prior to onset of the movement disorder. These 
symptoms are predominantly psychosis related, with paranoid delusions, behavioural 
disturbance, auditory and visual hallucinations. [33]
Heredo-degenerative disorders
A full summary of the clinical and genetic features of these disorders can be seen in 
Table 2.
Huntingtons disease
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Psychiatric symptoms described in patients with Huntingtons disease (HD) include 
depression, anxiety, irritability, apathy, OCD and psychosis. A large European 
epidemiological study (n=1766) found psychiatric symptoms to be the presenting 
feature in 19.6% of patients, with 39.3% developing severe symptoms during the 
course of the disorder.[34] The severity and likelihood of developing psychiatric 
symptoms appear independent of the number of trinucleotide repeat expansions, 
although both cross-sectional and longitudinal studies have noted that proximity to 
onset of motor symptoms increased the likelihood of developing psychiatric 
symptoms, particularly affective forms (p<0.01).[35-37] A single case series of 
individuals with juvenile HD (n=12) found depression (n=3), behavioural disorders 
(n=3) and Obsessive-Compulsive behaviour (n=2) to be most common.[38]
Rates of depression have varied between studies (33-69%), although case-control 
comparison has found major depressive disorder (MDD) to be significantly increased 
in both pre-motor symptomatic (p=0.001) and symptomatic (p<0.001) mutation 
carriers.[39] Affective symptoms are also likely to present early in the disease course, 
with increased rates of depression, attempted suicide and irritability scores in those 
with early HD compared to controls (p<0.05).[40]
Anderson et al found >50% of their cohort to demonstrate at least one OCD symptom
subtype with aggressive obsessions (26%) and contamination obsessions (22%) being 
most common (n=1642).[41] Some studies have found that the likelihood of 
developing OCD-type symptoms increases with disease severity and is linked to a 
higher level of other psychiatric co-morbidity (p<0.001).[42] Others have noted that 
OCD-type symptoms are more evident in pre-symptomatic mutation carriers 
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compared to controls (p=0.003), with obsessive worrying and perceived cognitive 
errors being prominent (p<0.05).[39, 43]
A 9% lifetime risk of schizophrenia has been reported in HD cohorts (n=154), with 
delusions more common than hallucinations (11% vs. 2%), and a trend towards an 
increased rate of non-affective psychosis compared to healthy controls (p=0.06).[39]
Onset of psychotic symptoms also appears to be linked to onset of motor symptoms, 
with a younger age at onset observed in those with a higher number of CAG 
repeats.[44]
Dentatorubral-pallidoluysian atrophy (DRPLA)
Prevalence of psychiatric symptoms in those with DRPLA mutations has been 
reported to be as high as 10%, with larger case series describing psychosis, 
depression, irritability and anxiety.[45-47] There is also a suggestion that psychotic 
symptoms, particularly delusions, are more common in those with shorter CAG 
repeats.[48]
Wilsons disease
A retrospective assessment of 195 cases found 51% to have evidence of psychiatric 
disturbance during the course of their illness. Presentation with psychiatric symptoms 
appears to occur in an older age group (mean age 25.3 years), compared to those with 
initial neurological features, and a gender difference of increased ritualistic behaviour 
and emotional lability amongst females (p<0.05).[49-51] Comparison with matched 
healthy controls found significant excesses of lifetime MDD (p=0.001) and bipolar 
disorder (p=0.001) in those with Wilsons disease, while similar rates of panic 
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disorder (p=0.922) and total anxiety disorder (p=0.215) were observed between the 
two groups.[52]
Neurodegeneration with Brain Iron Accumulation (NBIA)
Psychiatric assessment of a cohort of patients with PKAN (pantothenate kinase 
associated neurodegeneration), due to PANK2 mutations (n=16), identified psychiatric 
symptoms in 50% with behavioural disturbance, OCD, hyperactivity and depression 
described.[53] A comparison of 66 mutation-positive families with 32 mutation-
negative symptomatic families found an overall excess of psychiatric symptoms in the 
mutation-positive group (p<0.05).[54] PLA2G6-associated neuro-degeneration 
(PLAN) describes three over-lapping disorders; classic infantile neuroaxonal 
dystrophy (INAD), atypical neuroaxonal dystrophy (atypical NAD) and PLA2G6-
related dystonia-parkinsonism. Psychiatric symptoms are more frequently described 
in the latter two forms with a case series of atypical NAD describing autistic features, 
impulsivity, hyperactivity and emotional lability.[55] A larger case series (n=23) of
the more recently described Mitochondrial Membrane Protein-Associated 
Neurodegeneration (MPAN), found evidence of inattention, hyperactivity, emotional 
lability, depression, anxiety, impulsivity and compulsions.[56]
Kufor-Rakeb disease
Psychiatric symptoms have almost exclusively been reported in homozygous 
ATP13A2 mutation carriers with Kufor-Rakeb disease. A single case series described 
six members of the same family where only were two noted to have psychiatric 
symptoms. Both reported auditory hallucinations, with one additionally being 
diagnosed with paranoid schizophrenia, and the other with psychosis.[57]
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Genetic Dystonia
A summary of the clinical and genetic features of genetically determined dystonic 
disorders are summarised in Table 3.
DYT1
Systematic psychiatric assessment of motor affected DYT1 mutation carriers 
identified the risk of recurrent major depression to be greater in non-manifesting 
carriers (NMC) (RR=4.95) and manifesting carriers (MC) (RR=3.62) compared to 
controls, with depressive symptoms presenting at an earlier age and independent of 
motor symptom severity.[58]
DYT3 (X-linked Dystonia Parkinsonism (XDP)/Lubags disease)
Psychiatric symptoms are well recognised in XDP, with 9% of all mortality 
attributable to suicide. A single case-control study (n=14 cases, 14 controls) found 
almost 50% of affected individuals to have symptoms of at least one symptom type,
with anxiety related disorders (35.7%), social phobia (28.6%) and agoraphobia 
(21.4%) being most common. Major depressive symptoms were present in 14.3% 
with a significantly higher mean depression score in cases compared to controls 
(p=0.004).[59]
DYT5 dopa-responsive dystonia and other neurotransmitter disorders
GCH1 mutations (Segawas disease)
Large cohort studies have observed varying frequency of psychiatric symptoms
ranging from single cases to lifetime rates of 50% (n=34).[60] Affective disorders, 
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predominantly MDD, are the most commonly described, typically with onset in the 5
th
decade of life and a possible female predominance.[61-63] However, the single case-
control study to date found no significant differences with either depression (p=0.091) 
or anxiety scores (p=0.314).[64]
Aromatic L-amino acid decarboxylase (AADC) deficiency 
Two studies have examined psychiatric symptomatology in patients with AADC 
deficiency. The first assessed eleven patients identifying irritability and emotional 
lability in ten, with single cases of anxiety, panic attacks, ADHD and 
claustrophobia.[65] A more recent study found 7/8 with symptoms of irritability.[66]
Dopamine Transporter (DAT) Deficiency Syndrome
Several larger case series have identified early evidence of irritability with 6/11 
affected in the initial cohort and 3/8 in a more recent study.[67] Genetic association 
and linkage studies have also suggested a role for DAT in neurodevelopmental 
disorders, with the SLC6A3 A559V variant having been identified in individuals with 
ADHD, bipolar disorder and Autistic Spectrum Disorder (ASD).[68]
DYT6
A single case-control study compared eleven THAP1 mutation positive patients with 
82 mutation negative patients with dystonia. No significant difference was identified 
across a range of non-motor features, with the psychiatric focus being on anxiety 
(p=0.58) and sadness (p=0.5).[69]
DYT11 (Myoclonus Dystonia)
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Psychiatric symptoms have been widely published in SGCE mutation positive cohorts 
with OCD, anxiety, depression and alcohol misuse being the most frequently 
described.[70] Comparison of several genetically screened cohorts with matched 
controls have consistently identified an excess of Generalise Anxiety Disorder 
(GAD), OCD (predominantly compulsivity) and alcohol dependence amongst those 
with an SGCE mutation.[71-73]
DYT12 (Rapid-onset Dystonia Parkinsonsim)
Longitudinal and cross-sectional studies have consistently identified symptoms of 
depression and social phobia. Comparison of 29 mutation positive individuals and 27 
familial controls found significantly higher anxiety (p=0.025) and depression 
(p=0.025) scores, together with increased rates of psychosis (19% vs 0%) in motor 
affected individuals compared to controls. Mean age at onset of these symptoms was 
lower than is usually seen with more typical psychosis (15-24 years), with psychiatric 
symptom onset preceding development of the movement disorder in several 
cases.[74]
DYT28
Heterozygous variants in the KMT2B gene have recently been described in 
individuals with a complex progressive childhood-onset dystonia. Two case series 
have been reported to date with the larger of the two (n=27) describing symptoms of 
anxiety, ADHD, obsessive-compulsive traits and self-harm behaviour.[75]
Genetic Chorea
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Mutations in two distinct genes have been identified to cause genetically determined 
forms of chorea: NK2 homeobox 2 gene (NKX2.1), causing Benign Hereditary 
Chorea (BHC), and Adenylate cyclase 5 (ADCY5) involved in ADCY5-related 
dyskinesias. Three larger cohort studies of patients with the NKX2.1 mutation have 
identified relatively low rates of psychiatric symptomatology with 7/28 meeting 
diagnostic criteria for ADHD in a recently French study, while others have described 
single cases each of psychosis and OCD.[76-78] To date only a single cohort study 
(n=19) has reported psychiatric symptoms in those with ADCY5 mutations. Here 
psychosis and auditory hallucinations were identified in two cases, one of whom had 
recurrent episodes of psychosis with delusions and auditory hallucinations.[79]
Immune-mediated Movement Disorders
The clinical characteristics of immune-mediated movement disorders with psychiatric 
co-morbidity are summarised in Table 4.
Paediatric Autoimmune Neuropsychiatric Disorders Associated with 
Streptococcus (PANDAS)
The PANDAS concept has remained controversial, reflected in diagnostic difficulties 
in reported studies. This has been further augmented by the recent introduction of 
paediatric acute neuropsychiatric syndrome (PANS), a modified diagnosis involving 
development of an infection associated neuropsychiatric syndrome, but not 
specifically post-streptococcal. Examination of a large PANDAS cohort (n=50), 
identified ADHD (40%), oppositional defiant disorder (40%) and major depression 
(36%) as the most common forms of psychiatric symptoms. However, 
symptomatology may fluctuate, with emotional lability (66%), changes in personality 
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(54%) and bedtime fears/rituals (50%) described most frequently during subsequent 
episodes.[80] Other studies have identified high levels of OCD, with obsessions 
principally focused on the fear of harm to self or others (5/12) and compulsions 
predominantly hygiene related.[81] The relationship with OCD however, may be 
more complex with increased rates of OC personality disorder (11%), subclinical 
OCD (8%) and OCD (26%) amongst 1
st
-degree relatives (n=157) of those with
PANDAS.[82]
Results from case-control studies have varied with several studies observing no 
difference between PANDAS cases and controls.[83] In contrast, Murphy and 
colleagues found that those with PANDAS were more likely to have a dramatic onset 
of psychiatric symptoms (p<0.05) and clear periods of remission (p<0.05), 
particularly during treatment with antibiotics (p<0.01).[84] Others have found that 
rates of psychiatric symptoms may differ dependent on the methods of assessment, 
and that PANDAS-associated psychiatric symptoms are likely to vary in conjunction 
with the symptomatic fluctuation observed with the disorder.[85]
Sydenhams Chorea
Case-control analyses have identified increased rates of ADHD (p<0.01) and MDD 
(p<0.01) amongst those with Sydenhams chorea when compared to patients with 
Rheumatic fever, while comparison to matched healthy controls has found little 
difference in the rates of anxiety and depression.[86, 87] A similar case-control 
comparison reinforced an increased rate of ADHD (p=0.001), identified an excess of 
OCD (p=0.003) and found only those with persistent motor symptoms had an excess 
of ADHD compared to controls.[88] In contrast, a more recent study identified an 
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increased rate of depression amongst those with persistent motor symptoms (p=0.03) 
but no significant difference in the rates of ADHD or OCD.[89] Longitudinal 
observation of a single cohort (n=28) provides a potential explanation, describing 
temporal variation in the psychiatric phenotype with depression (69%) and anxiety 
(78%) highest during the episodes of chorea, and ADHD most pronounced following 
resolution of the movement disorder (36%).[90] However, a recent case-control 
comparison of standard treatment versus augmented IVIG therapy also found that 
those receiving standard treatment demonstrated poorer co-operation (p=0.009) and 
increased impulsivity (p=0.016).[91]
Several studies have specifically focused on symptoms of OCD and Obsessive-
Compulsive Symptoms (OCS). A recent case series (n=73) found 38.4% to meet 
diagnostic criteria for OCD with contamination (p=0.006) and religious (p=0.019) 
obsessions, and cleaning (p=0.003) and repeating (p=0.012) compulsions being most 
common.[92] An earlier case-control study found that the majority of patients (21/30) 
had abrupt onset of OCS symptoms within the first two months of the streptococcal 
infection. These patients also demonstrated a significant increase in resistance 
(p=0.005) and interference (p=0.008) at two months post-symptom onset compared to 
those with rheumatic fever with these effects waning over time.[93]
Anti-NMDA Receptor Encephalitis (anti-NMDAR)
Although anti-NMDAR encephalitis is a diffuse encephalitis, movement disorders 
and psychiatric symptoms are highly recognised features. Several studies have 
reported frequencies of 65-69% (n=40-577) of psychiatric disorders at presentation 
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with a consistent pattern of symptomatology including hallucinations (auditory and 
visual), psychosis and agitation.[94-97] These findings are also supported by case-
control studies where rates of psychosis (p<0.001), hallucinations (p<0.05) and 
personality change (p<0.0001) were significantly higher than cohorts of mixed 
infective encephalitidies and symptomatic, antibody-negative groups.[98] Similar 
results are also seen in pediatric cohorts where up to 87.5% (n=32) presented with 
psychiatric or behavioral changes, predominantly involving agitation, aggression and 
psychosis.[99] Long-term follow-up of twenty-three antibody-positive cases found 
eighteen had psychiatric symptoms during subsequent relapses, while 50% of cases at 
12-60 months from symptom onset in another study had ongoing behavioural or 
cognitive difficulties. [100, 101]
Basal ganglia Encephalitis
Several cohort studies have reported psychiatric symptoms, noting a wide range in 
overall rates of psychiatric disturbance (49%-88%), but similar levels of depression 
and anxiety (38% and 40%).[102, 103] In contrast a more recent study of 12 patients 
with anti-DR2 basal ganglia antibodies found psychiatric symptoms in nine, with 
agitation (5/12) and psychosis or hallucinations (3/12) being most common. 
Approximately half of all cases recovered fully, while residual psychiatric symptoms 
were evident in the remainder.[104]
Opsoclonus-Myoclonus Ataxia Syndrome
A retrospective study using parent-completed questionnaires (n=105) identified rage 
attacks (79%), opposition defiant disorder (65%), OCS (58%) and hyperactivity 
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(47%) as the most common symptom subtypes.[105] Behavioural disturbance has also 
been highlighted in a number of other cohorts (n=51), with irritability reported during 
the acute phase, and rage (51%) and hyperactivity (55%) in the longer term.[106, 107]
Retrospective analysis (n=101) found a potential link with disease course, behavioral 
disturbance being noted in 39% of those with a monophasic or intermediate illness 
compared to 74% of those with a chronic-relapsing form (p=0.006).[108] These 
findings have also been replicated in the single case-control study to date, 
demonstrating significantly higher scores relating to attention difficulties, social and 
thought problems compared to healthy controls.[109]
Discussion
The evidence summarised in Figure 3 suggests that patterns of psychiatric phenotypes
or clusters of symptoms are associated with particular movement disorders. The most 
common disorders to emerge were anxiety disorders (GAD), mood disorders 
(depressive disorders) and schizophrenia and other psychotic disorders (psychosis). 
These symptoms were common across genetic and immunological disorders, as well 
as neurodegenerative and neurodevelopmental aetiologies. Frequent discussion 
focuses on whether these symptoms, especially mood disorders, represent primary or 
secondary-reactive features of the movement disorder phenotype. However, the 
consistent pre-motor onset of depressive symptoms in those with genetically 
determined parkinsonism and recurrent episodes of major depressive disorder in 
DYT1-positive patients suggests a more complex rather than causal relationship.
Interestingly, while some of the disorders discussed in this review have evidence of a 
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broad range of psychiatric symptoms (e.g. PANDAS: ADHD, ODD, depressive 
disorder, irritability, GAD, OCD), others have a much narrower spectrum of 
symptoms, e.g. DJ-1 (psychosis and GAD). Within individual psychiatric diagnoses, 
subsets of symptoms also differ between distinct movement disorder types. Case-
control studies have demonstrated increased rates of OCD in both HD and Myoclonus 
Dystonia (DYT11). However, there was a greater tendency towards contamination-
type obsessions in the former and a greater emphasis on compulsivity in the latter. 
Although clear pathophysiological mechanisms explaining both motor and psychiatric 
symptoms have yet to be fully elucidated, a comprehensive view of the distinct 
patterns of symptoms between disorders is important in contributing to robust 
mechanistic understanding.
Tourettes Syndrome, although a widely recognised movement disorder with 
overlapping psychiatric phenotype, is not discussed in detail in this review as no 
definitive genetic or immunological aetiology has been consistently identified to date.
Tourettes Syndrome typically involves motor and vocal tics, together with 
psychiatric symptoms including ADHD, OCD, anxiety and mood disorders. Many 
studies have sought to determine the underlying aetiology of Tourettes Syndrome
with evidence suggesting both complex genetic and immunological contributions in
the pathophysiological process.[110, 111] An added benefit of improved mechanistic 
understanding of the disorders discussed in this review is the opportunity to further 
explore disorders, such as Tourettes Syndrome, in which more complex aetiological 
processes are likely to be involved.
Overall this review has demonstrated a general paucity of case-controlled, systematic 
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assessments of psychiatric symptoms across many of the movement disorders 
discussed, with considerable inconsistency in the assessment techniques employed
(Supplementary Figure 1). Of the 404 publications included only 64 involved 
comparison of the genetically/immunologically defined cohort to a control group 
(15.8%), and of these only 53 involved use of standardised questionnaires. Many of 
the control groups included unaffected family members, who although potentially 
controlled for environmental factors, their symptoms may also have been influenced 
by additional genetic variables, while others used groups unmatched for both gender 
and age. Finally, the focus of the questionnaires used varied frequently between 
studies, with some using broad diagnostic tools while others used questionnaires 
targeted at assessing specific disorders. Choice of questionnaires often appeared 
influenced by findings from previous case reports/case series, which combined with 
variations in assessment may have influenced findings in some disorders.
Conclusion
This review clearly illustrates that many movement disorders are associated with 
psychiatric co-morbidity. Although disease mechanisms causing psychiatric 
symptoms are largely undetermined, the underlying movement disorder aetiology, 
affected neural networks and environmental factors such as those governing reactive 
responses to a chronic neurological disorder are all likely to play a role (Figures 1 and 
2). As the psychiatric phenotypes of movement disorders become increasingly 
refined, along with mechanistic insights from cellular- and systems-based approaches,
it is hoped that future work will provide a model of pathogenesis that encompasses
both motor and non-motor symptoms. Clinical recognition and awareness of the co-
existence of movement disorders and psychiatric symptoms is therefore of relevance 
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to both neurologists and psychiatrists. Early recognition of these disorders is vital to 
allow prompt initiation of appropriate therapy and involvement of multidisciplinary 
allied specialities and support services.
With the rapid advancement of technologies, the rate at which novel genetic and 
immunological aetiologies for movement disorders are identified is ever increasing. 
Recognition of the significant prevalence of psychiatric co-morbidity should drive 
early systematic assessment for such symptoms in patients with movement disorders. 
The temporal pattern of onset of both motor and psychiatric symptoms is also an 
important diagnostic clue, and should form a core component of all clinical 
assessments. Collectively, this information, as well as improving understanding of the 
underlying aetiology or network disruption, will also form important outcome 
measures for future clinical trials.
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Table 1: Genetic Parkinsonism 
PARK locus/
Disorder
Epidemiology
Causative 
gene
Inheritance Motor phenotype Psychiatric phenotype
Additional clinical 
characteristics
PARK1/4
(168601)
Rare. Disease causing in 
~2.5% of unrelated affected 
carriers
SNCA AD
L-dopa responsive 
parkinsonism, cortical 
myoclonus
Depression+
Hallucinations+ Delusions+
Dementia, speech disturbance, 
autonomic dysfunction
PARK8
(607060)
5% familial and 1-2% 
sporadic PD in European 
populations. G2019S most 
common mutation
LRRK2 AD Tremor dominant Parkinsonism
Depression++ Apathy++
Hallucinations++
Anxiety+ Irritability+
Suicidal Ideation+
Amyotrophy, dystonia, 
PARK2
(600116)
2.5% - 8.2% in <45 years Parkin AR
Onset <45 years, LL dystonia, 
L-dopa responsive, dyskinesias
Depression++
Psychosis+ Paranoia+ Panic 
Attacks+
Leg tremor, autonomic & 
peripheral neuropathy
PARK6
(605909)
Homozygous and compound 
heterozygous mutations 
accounting for 4-5% of AR 
disease & 1-2% of sporadic 
cases
PINK1 AR
Young-onset, slow disease 
progression, L-dopa responsive
Depression+ Anxiety+
Schizophrenia+ OCD+ -
PARK7
(606324)
Very rare  <1% of EOPD 
cases
DJ-1 AR
Young-onset, slow disease 
progression, L-dopa responsive
Anxiety+ Psychosis+
Amyotrophic lateral sclerosis, 
scoliosis, blepharospasm
Gauchers disease
(168600)
1 in 20,000 live births GBA AR
Typical patterns of Lewy body 
disease. 
Depression++ Anxiety++ 
Apathy++ Psychosis++
Hepatosplenomegaly, liver 
dysfunction, skeletal disorders
Niemann Pick Type C
(257220: NPC1, 
607625: NPC2)
1:100,000-150,000 live births
NPC1 & 
NPC2
AR
Cerebellar ataxia, saccadic 
disturbance, supranuclear gaze 
palsy
Psychosis+ Hallucinations+
Behavioural disturbance+
Dysphagia, Dysarthria, 
Epilepsy, Cataplexy, 
Cognitive impairment
Key: AD: Autosomal Dominant, ADHD: Attention Deficit Hyperactivity Disorder, AR: Autosomal Recessive, L-dopa: levodopa, LL: lower limb, OCD: 
Obsessive Compulsive Disorder, PD: Parkinsons disease. + Reported in large case series, ++ Reported in case-control studies, - no features reported to date., 
¹ no psychiatric symptoms reported in large case series (n>5) or case-control studies.
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Table 2: Heredodegenerative disorders
Disorder Epidemiology Causative gene Inheritance Motor phenotype Psychiatric phenotype Additional characteristics
Huntingtons disease
(613004)
5-7/100,000 in 
Western 
populations
HTT AD
Chorea, Dystonia, 
Bradykinesia, Rigidity
Depression++ OCD++
Psychosis++ apathy+ 
irritability+ aggressive
behaviour+
Cognitive impairment, Dysarthria, 
Dysphagia, falls
Dentatorubral-pallidoluysian 
atrophy (DRPLA)
(607462)
0.2-0.7/100,000 
in Japan.
ATN1 (CAG 
repeat)
AD
Myoclonus, Ataxia, 
Chorea
Psychosis+ Depression+ 
Anxiety+ Irritability+
Seizures, dementia
Wilsons disease
(606882)
30 per million 
population
ATP7B AR
Chorea, tremor, dystonia, 
parkinsonism
Depression++ Mood 
disorder++ Psychosis+ 
Irritability+ Personality 
change+ Anxiety+
Hepatosplenomegaly
Cognitive impairment
Dysarthria
Pantothenate Kinase 
associated neurodegeneration 
(PKAN)
(234200)
Rare PANK2 AR
Typically childhood 
onset, extrapyramidal
features, rapid 
immobility. Atypical: 
onset 2
nd
-3
rd
decade, 
slower progression, 
maintained mobility
Behavioural 
disturbance++
Depression++
Emotional lability++
OCD+
Dysarthria, psychomotor delay
PLA2G6-associated 
neurodegeneration 
(PLAN)/PARK14
(603604)
Rare PLA2G6 AR
Sub-acute onset dystonia-
parkinsonism 
Behavioural disturbance+
Impulsivity+ Emotional 
lability+
Eye movement abnormalities, 
pyramidal tract signs, cognitive 
decline
Beta-propeller protein-
associated neurodegeneration 
(BPAN)
(234200)
Rare WDR45
X-linked 
dominant
L-dopa responsive 
dystonia, parkinsonism, 
ataxia, spasticity
¹
Epilepsy, dementia, sleep 
disturbance, ocular defects, Rett-
like hand stereotypies
Mitochondrial membrane 
protein-associated 
neurodegeneration (MPAN)
(614298)
Rare C19ORF12 AR
Gait disturbance, spastic 
paraparesis, dystonia
Emotional lability+ 
anxiety+ compulsions+ 
hallucination+
depression+
-
COASY Protein Associated 
Neurodegeneration (CoPAN)
Rare COASY AR
Spasticity, dystonia, 
paraparesis with later 
¹ Cognitive impairment
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(615643) parkinsonism
PARK9
Kufor-Rakeb disease 
(606693)
Rare ATP13A2 AR
Rapidly progressive 
parkinsonism, facial-
faucial-finger mini-
myoclonus, vertical 
supra-nuclear gaze palsy
Psychosis+
Hallucinations+
Cognitive impairment, axonal 
peripheral neuropathy
Key: AD: Autosomal Dominant, ADHD: Attention Deficit Hyperactivity Disorder, AR: Autosomal Recessive, L-dopa: levodopa, OCD: Obsessive Compulsive Disorder.
+ Reported in large case series, ++ Reported in case-control studies, - no features reported to date, ¹ no psychiatric symptoms reported in large case series (n>5) or case-
control studies.
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Table 3: Genetic Dystonia
Disorder
(MIM number)
Epidemiology Causative 
Gene
Inheritance Motor Phenotype Psychiatric Phenotype Additional Clinical 
Characteristics
DYT1
(605204)
Mutation frequency: 
0.17/100,000
GAG deletion 
of TorsinA
AD with reduced 
penetrance(~30%)
Range from mild focal dystonia to 
generalised form
Early onset recurrent major 
depression++
-
DYT2
(224500)
Unknown No gene as yet
identified
Suggested AR Predominantly LL dystonia with 
possible subsequent generalisation
Nil reported to date Identified in Sephardic Jewish and 
Spanish gypsy families.
DYT3
XDP/Lubags disease
(313650)
Worldwide: <1/1,000,000
Philippines: overall 
1/322000, men 1/4000
TAF1 X-Linked Focal/segmental dystonia with 
later generalisation. Parkinsonian 
features in later stages 
Depression++ Anxiety++ 
Social phobia++
Agoraphobia++
-
DYT4 Whispering 
dysphonia
(602662)
Unknown TUBB4 AD Craniocervical dystonia with 
prominent laryngeal dystonia. 
Frequent generalisation
Nil reported to date Thin face and body habitus.
Partial response to alcohol and 
propranolol.
DYT5a Segawas 
disease
(600225)
0.5/1,000,000 (Nygaard 
1993)
GCH1 AD with reduced 
penetrance 
LL dystonia with subsequent 
generalisation.  Diurnal 
fluctuation. Parkinsonism, 
dystonic tremor
Depression+
anxiety+ OCD+
Spastic paraparesis.
DYT5b
(605407)
Rare TH AR Hypokinesia, rigidity and 
encephalopathy
¹ -
DYT5b
(612716)
Rare SPR AR Onset 1st year of life, diurnal 
fluctuation, ataxia, myoclonus
Inattention+ Irritability+ 
Anxiety+ Hyperactivity+ 
Aggression+ OCD+
Delayed motor development, 
cognitive impairment
Vesicular Monoamine 
Transporter 2 
(193001)
Rare SLC18A2 AR Hypotonia, parkinsonism, dystonia Depression+ Developmental delay, improved 
motor symptoms with dopamine 
agonists, worsening with L-dopa
Aromatic L-amino acid 
decarboxylase deficiency
(608643)
Rare DDC AR Hypotonia, oculgyric crises Irritability+ Emotional 
lability+
Developmental delay
Dopamine Transporter 
Deficiency Syndrome
(613135)
Rare SLC6A3 AR Early infantile and juvenile 
parkinsonism dystpnia
Irritability+
DYT6
(609520)
Unknown, THAP1 AD (~60% 
penetrance)
Adult onset torsion dystonia. 
Prominent cranio-cervical and 
laryngeal involvement
Nil reported to date Women more commonly affected 
than men
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DYT7
(602124)
Unknown No gene as yet 
identified
Unknown Focal dystonia typically involving 
neck, eyes or hands
Nil reported to date -
DYT8 Paroxysmal Non-
Kinesigenic Dyskinesia
(609023)
Rare MR-1 AD Intermittent attacks lasting 10 
minutes-1 hour. Dystonia, chorea, 
ballism, blepharospasm
Nil reported to date Attacks precipitated by alcohol, 
coffee, stress, exercise.
DYT10 Paroxysmal 
Kinesigenic Dyskinesia
(614386)
1/150,000 PRRT2 AD (incomplete 
penetrance)
Attacks of isolated/mixed 
dystonia, chorea, athetosis, 
ballism.
Depression+ ADHD+ 
Behavioural disturbance+
Associated with other clinical 
phenotypes: ICCA, episodic ataxia, 
hemiplegic migraine
DYT11 Myoclonus 
Dystonia 
(604149)
Rare SGCE AD (reduced 
penetrance due to 
maternal 
imprinting)
Truncal & UL myoclonus +/-
cervical/hand dystonia. 
OCD++ GAD++ alcohol 
dependence++ 
Depression++ Personality 
disorder+
Motor symptoms typically alcohol 
responsive. Additional clinical 
characteristics observed with WGD 
cases
DYT12 Rapid-onset 
Dystonia Parkinsonism
(182350)
Rare ATP1A3 AD with reduced 
penetrance
Sudden onset raustro-caudal 
pattern of dystonia and gait 
instabiliity
Psychosis++ Anxiety++
Depression++ Suicidal 
ideation+
Symptoms typically develop in 
response to a physical or 
psychological stressor
DYT13
(607671)
Unknown No gene as yet 
identified
AD Idiopathic torsion dystonia 
(predominant upper body and 
cranio-cervical involvement)
Nil reported to date -
DYT15
(607488)
Reported in a single 4-
generation family
No gene as yet 
identified
Possible AD Myoclonic dystonia involving 
trunk, hands and upper limbs
Nil reported to date Alcohol responsive
DYT16
(603424)
Reported in two 
consanguineous Brazilian 
families and a single 
German case
PRKRA AR 2 forms: 1) pure generalised 
dystonia 2) dystonia-parkinsonism
Aggression+ Cognitive impairment reported in 
two cases
DYT17
(612406)
Reported in single 
consanguineous Lebanese 
family
No gene as yet 
identified
AR Primary focal torsion dystonia 
with segmental or generalised 
spread
Nil reported to date -
DYT18 GLUT1 
Deficiency Syndrome 2
(138140)
1 in 90,000 SLC2A1 AD Dyskinetic episodes, typically 
distal lower limb dystonia. May be 
triggered by exercise or hunger
¹ Associated with ataxia, spasticity, 
seizures, encephalopathy and 
haemolytic anaemia. 
DYT20 Paroxysmal Non-
Kinesigenic Dyskinesia 2
(138140)
Reported in single 4-
generation Canadian 
family
No gene as yet 
identified
AD Intermittent dystonia with 
symmetrical involvement of the 
hands and feet
Nil reported to date -
DYT21
(614588)
Reported in single large 
Swedish family
No gene as yet 
identified
AD (incomplete 
penetrance)
Focal dystonia, predominantly 
blepharospasm and torticollis. 
Nil reported to date -
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DYT23
(614860)
Reported in single German 
family
No gene as yet 
identified
AD Adult onset cervical dystonia with 
head and limb tremor
Nil reported to date -
DYT24
(615034)
ANO3 AD Adult-onset cervical dystonia with 
laryngeal involvement and upper 
limb tremor
Nil reported to date -
DYT28
(617284)
Reported in 31 unrelated 
individuals worldwide
KMT2B AD Childhood-onset progressive 
dystonia, initially involving the 
lower limbs and progressing to the 
orofacial region
Anxiety+ ADHD+ 
Obsessive-Compulsive 
traits+ self-harm 
behaviours+
Dysmorphic facial features, 
microcephaly, mild/moderate 
cognitive impairment, eye 
movement abnormalities, seizures
Key: AD: Autosomal Dominant, ADHD: Attention Deficit Hyperactivity Disorder AR: Autosomal Recessive, DBS: Deep Brain Stimulation, GAD: Generalised Anxiety 
Disorder, GP: Globus Pallidus Internus,i ICCA: infantile convulsions with choreoathetosis, OCD: Obsessive-Compulsive Disorder. +Reported in large case series, 
++Reported in case-control studies, - no features reported to date, ¹ no psychiatric symptoms reported in large case series (n>5) or case-control studies, nil reported to date: 
indicates no psychiatric symptoms reported in case reports, small case series (n<5), large case series (n>5) nor case-control studies.
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Table 4: Immunological disorders
Disorder Epidemiology Pathophysiology Inheritance Motor Phenotype Psychiatric phenotype Additional clinical 
characteristics
Paediatric 
Autoimmune 
Neuropsychiatric 
Disorders associated 
with streptococcus 
(PANDAS), 
Paediatric Acute 
neuropsychiatric 
syndrome (PANS)
Uncertain, probably 
rare.
Unknown. Infection 
associated immune 
dysregulation of unclear 
aetiology.
Uncertain, increased 
rates of autoimmunity 
and tics, OCD in first 
degree relatives
Relapsing-remitting 
hyper-motor activity 
including: tics (e.g. eye 
blinking, tongue 
protrusion) 
Anxiety++ Irritability++
Oppositional disorder++
OCD+ ADHD+ Depression+ 
Emotional lability+
Deterioration in 
handwriting
Higher rates of 
tonsillectomies and 
adenoidectomies. 
Sydenhams chorea 0.5/100,000 annual 
incidence of ARF in 
school age children.
10-30% of children with 
ARF affected by 
Sydenhams chorea
Associated with Group A 
Streptococcal infection.
Increased rate of ARF 
in families of those 
diagnosed with 
Sydenhams chorea
Chorea, hypotonia, 
dysarthria and saccadic 
slowing
OCD++ ADHD++ 
Depression++ Psychosis++
Anxiety+ Oppositional 
disorder+ Behavioural 
disturbance+
Most cases have 
symptomatic 
improvement at 2 
years.
NMDA Receptor 
Encephalitis
Approximately 4-10% 
of all patients 
hospitalised for 
encephalitis
Hypofunction of the NMDA 
receptor secondary to 
autoantibodies targeting the 
NR1a subunit.
Not known Orofacial dyskinesias, 
choreoathetosis, dystonia, 
myoclonus, tremor and 
ballismus
Psychosis++Hallucinations++ 
Personality change++
Anxiety+ Agitation+
Paranoia+ Aggression+
Hyperactivity+
Progression to 
encephalopathy, 
movement disorder,, 
mutism, catatonia and 
autonomic instability.
Basal ganglia
Encephalitis
Rare, <2% of all 
encephalitis in children
Autoantibodies targeting D2 
receptor in the basal ganglia
Not known Dystonia, parkinsonism, 
chorea, oculogyric crisis
Depression+ Anxiety+
Apathy+ Agitation+
Psychosis+ OC symptoms+
Emotional lability+
Encephalopathy, 
radiological basal 
ganglia involvement
Opsoclous-myoclonus 
ataxia
Rare, 2-3% of children 
with neuroblastoma
Unknown, possible 
autoantibodies or other 
acquired immune 
Not known Myoclonus, ataxia, 
opsoclonus
Irritability++ Aggression+
Behavioural disturbance+
Opposition defiant disorder+
Cognitive impairment, 
language difficulties,
Psychiatric Co-morbidity in Movement Disorders
Peall et al 2017
41
mechanisms OCD+ ADHD+
Key: ADHD: Attention Deficit Hyperactivity Disorder, ARF: Acute Rheumatic Fever, GAD: Generalised Anxiety Disorder, OCD: Obsessive-Compulsive Disorder.
+Reported in large case series, ++Reported in case-control studies.
Indirect
Pathway
Direct
Pathway
Dopamine
Striatum
SNc
STN
GPe
Cortex
Thalamus
SNr
GPi
InhibitoryPathway
Glutamate
PPN
GABA
GABA
GABA
GABA
Glutamate
Glutamate
Glutamate
ExcitatoryPathway
5.Schizophrenia
4.ADHD
3.Depression
2.OCD
1.Anxiety,Depression,Suicide
Cerebellum
A.Idiopathic
Parkinsonsdisease
B.Hun ngtonsdisease
C.Wilsonsdisease
C.Wilsonsdisease
D.BrainIron
accumula on
disorders
E.DYT3
F.DYT11
G.Sydenhamschorea
H.Basalgangliaencephali s
Tryptophan 
Phenylalanine 
5-hydroxytryptophan
Tetrahydrobiopterin
Serotonin
Tyrosine
Levodopa
Glutamine
Glutamate
GABA
Dopamine Noradrenaline
Key for metabolites and receptors 
      Dopamine 
      Serotonin 
      Noradrenaline 
      Glutamate 
      GABA      
9. SNRIs 
Post-synaptic membrane 
5-HT2A/2C 
6.Serotonin receptor 
interaction 
SERT a2 
a bD1  D2  GABAA iGluR mGluR 
4. SSRIs 
5. Disrupted serotonin 
neurotransmission 3. Disrupted 
glutamate 
neurotransmission 
1. Reduced GABA 
neurotransmission 
2. Allosteric change 
to GABA receptors 
8. Dopamine 
antagonists 
7. Dopamine agonists 
and DAT antagonists 
5-HT1A 
DAT 
Disordersusually
®rstdiagnosedin
infancy,
childhoodor
adolescence
Psychiatric
Disordersubtype
Substance
relateddisorders
Schizophrenia
andother
psycho c
disorders
Mooddisorders
Anxietydisorders
Unclassi®ed
disorders
ODD
PANDAS,
SydenhamsChorea,
Opsoclonus-
Myoclonus
Schizophrenia
PINK1
Psychosis
SNCA,LRRK2,Parkin,
DJ-1,GBA,NPC,HD,
DRPLA,WD,MPAN,
Kufor-Rakeb,DYT12,
SydenhamsChorea,
an-NMDAR
encephalis,Basal
gangliaencephalis
Alcoholrelated
disorders
DYT11
Depressive
disorders
SNCA,LRRK2,Parkin,
PINK1,GBA,HD,DRPLA,
WD,PKAN,MPAN,DYT1,
DYT3,GCH1,VMAT2,
DYT10,DYT12,PANDAS,
SydenhamsChorea,,
Basalgangliaencephalis
ADHD
DYT10,PANDAS,
SydenhamsChorea,
Opsoclonus-
Myoclonus
Apathy
LRRK2,GBA,HD
GAD
LRRK2,PINK1,DJ-1,
GBA,DRPLA,WD,PKAN,
MPAN,DYT3,GCH1,
SPR,DYT11,DYT12,
PANDAS,Sydenhams
Chorea,an-NMDAR
encephalis,Basal
gangliaencephalis
OCD
PINK1,HD,PKAN,
MPAN,GCH1,SPR
DYT11,PANDAS,
SydenhamsChorea,
Basalganglia
encephalis
Opsoclonus-myoclonus
Panica acks
Parkin
Irritability
LRRK2,HD,DRPLA,
WD,SPR,AADC,
DAT,PANDAS,
Opsoclonus-
myoclonus
Emo onal
lability
PKAN,PLA2G6,
MPAN,AADC,Basal
gangliaencephalis
Behavioural
disturbance
NPC,HD,WD,PKAN,
PLA2G6,DYT10,
Opsoclonus-
myoclonus
